@Article{Synowiec2010,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="14",
number="2",
year="2010",
title="Status of the BRCA1 gene and incidence of hereditary ovarian cancer",
abstract="Ovarian cancer is the leading cause of mortality in women with gynaecological cancers. Cytoreductive surgery has been considered as a mainstay in manage­ment of ovarian cancer for a long time. Further chemotherapy, based on platinum compounds and taxanes  given in an adjuvant setting, allows  5-year survival to be achieved in 10-30% of ovarian cancer patients. Among these cases, it is thought that 5-10% of patients have familial or hereditary disease in which mutations within BRCA genes are the main culprits of 80-90% of ovarian cancer sufferers. The risk of ovarian cancer development in carriers of a mutated BRCA1 gene is 16-60%, which underlines the great need for  a precise tool in the form of molecular tests. Now it is time for development of a direct-to-consumer (DTC) strategy that offers commercially available molecular tests with wide utility.",
author="Synowiec, Agnieszka
and Wcisło, Gabriel
and Bodnar, Lubomir
and Szarlej-Wcisło, Katarzyna
and Cieślak, Agata
and Sielużycka, Joanna
and Szczylik, Cezary",
pages="72--78",
doi="10.5114/wo.2010.13915",
url="http://dx.doi.org/10.5114/wo.2010.13915"
}